title: Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
abstract: While the oncogenic human papillomavirus (HPV) types with the greatest medical impact are clustered within the α9 and α7 species, a significant fraction of cervical cancers are caused by α5, α6, and α11 viruses. Benign genital warts are caused principally by the α10 viruses HPV6 and HPV11. In an effort to achieve broad protection against both cervical cancer- and genital wart-associated types, we produced at high levels in bacteria a multimeric protein (α11-88x8) fusing eight polypeptides corresponding to a protective domain comprising L2 residues ∼11 to 88 derived from HPV6 (α10), HPV16 (α9), HPV18 (α7), HPV31 (α9), HPV39 (α7), HPV51 (α5), HPV56 (α6), and HPV73 (α11) and a truncated derivative with the last three units deleted (α11-88x5). Mice were immunized three times with α11-88x8 or α11-88x5 adjuvanted with alum or the licensed HPV vaccines and challenged intravaginally with HPV6, HPV16, HPV26, HPV31, HPV33, HPV35, HPV45, HPV51, HPV56, HPV58, or HPV59 pseudovirions. The α11-88x5 and α11-88x8 vaccines induced similarly robust protection against each HPV type tested and indistinguishable HPV16-neutralizing antibody titers. Passive transfer of α11-88x8 antisera was protective. Further, rabbit antisera to α11-88x8 and α11-88x5 similarly neutralized native HPV18 virions. These findings suggest that immunologic competition between units is not a significant issue and that it is not necessary to include a unit of L2 derived from each species to achieve broader protection against diverse medically significant HPV types than is achieved with the licensed HPV vaccines.
authors.affiliation: Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
authors.forename: Subhashini
authors.initials: S
authors.lastname: Jagu
authors.forename: Kihyuck
authors.initials: K
authors.lastname: Kwak
authors.forename: John T
authors.initials: JT
authors.lastname: Schiller
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Lowy
authors.forename: Harold
authors.initials: H
authors.lastname: Kleanthous
authors.forename: Kirill
authors.initials: K
authors.lastname: Kalnin
authors.forename: Chenguang
authors.initials: C
authors.lastname: Wang
authors.forename: Hsu-Kun
authors.initials: HK
authors.lastname: Wang
authors.forename: Louise T
authors.initials: LT
authors.lastname: Chow
authors.forename: Warner K
authors.initials: WK
authors.lastname: Huh
authors.forename: Kilvani S
authors.initials: KS
authors.lastname: Jaganathan
authors.forename: Sudha V
authors.initials: SV
authors.lastname: Chivukula
authors.forename: Richard B S
authors.initials: RB
authors.lastname: Roden
mesh_terms: D052685:Alphapapillomavirus / Q000145:classification* / Q000235:genetics* / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D036022:Capsid Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D005260:Female; D005838:Genotype; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology*; D053918:Papillomavirus Vaccines / Q000235:genetics / Q000276:immunology; D010802:Phylogeny; D011817:Rabbits
chemical_list: D000914:Antibodies, Viral; D036022:Capsid Proteins; D053918:Papillomavirus Vaccines
references.citation: Nat Rev Cancer. 2006 Oct;6(10):753-63
references.pmid: 16990853
references.citation: J Virol. 1996 Sep;70(9):5875-83
references.pmid: 8709207
references.citation: Virology. 1997 Aug 4;234(2):261-6
references.pmid: 9268157
references.citation: Vaccine. 2006 Aug 31;24 Suppl 3:S3/140-6
references.pmid: 16950001
references.citation: J Infect Dis. 2011 Dec 15;204(12):1886-92
references.pmid: 22013227
references.citation: PLoS One. 2013;8(1):e55538
references.pmid: 23383218
references.citation: Vaccine. 2004 Jan 26;22(5-6):670-80
references.pmid: 14741159
references.citation: Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11553-7
references.pmid: 8524802
references.citation: Br J Cancer. 2006 Dec 4;95(11):1459-66
references.pmid: 17117182
references.citation: J Virol. 2007 Nov;81(21):11585-92
references.pmid: 17715230
references.citation: Cancer Res. 2006 Dec 1;66(23):11120-4
references.pmid: 17145854
references.citation: Cell Host Microbe. 2010 Sep 16;8(3):260-70
references.pmid: 20833377
references.citation: Int J Cancer. 2004 Aug 20;111(2):278-85
references.pmid: 15197783
references.citation: Lancet. 2009 Jul 25;374(9686):301-14
references.pmid: 19586656
references.citation: PLoS One. 2011 Feb 08;6(2):e16405
references.pmid: 21346798
references.citation: Virology. 1995 Jan 10;206(1):126-35
references.pmid: 7831768
references.citation: J Virol. 1994 Nov;68(11):7570-4
references.pmid: 7523700
references.citation: J Virol. 1996 May;70(5):3298-301
references.pmid: 8627814
references.citation: J Infect Dis. 1999 Mar;179(3):612-8
references.pmid: 9952367
references.citation: Virology. 2010 May 25;401(1):70-9
references.pmid: 20206957
references.citation: Lancet Infect Dis. 2012 Oct;12(10):781-9
references.pmid: 22920953
references.citation: Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25
references.pmid: 16949997
references.citation: J Virol. 2007 Dec;81(24):13927-31
references.pmid: 17928339
references.citation: J Natl Cancer Inst. 2009 Jun 3;101(11):782-92
references.pmid: 19470949
references.citation: Clin Vaccine Immunol. 2012 Jul;19(7):1075-82
references.pmid: 22593236
references.citation: J Virol. 2002 May;76(10):4723-33
references.pmid: 11967289
references.citation: Virology. 1989 Jul;171(1):294-7
references.pmid: 2545034
references.citation: Vaccine. 2002 Oct 4;20(29-30):3456-64
references.pmid: 12297390
references.citation: Virology. 2000 May 10;270(2):254-7
references.pmid: 10792983
references.citation: Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180-4
references.pmid: 1334560
references.citation: Cancer Discov. 2011 Oct;1(5):408-19
references.pmid: 22586631
references.citation: Lancet Oncol. 2012 Jan;13(1):100-10
references.pmid: 22075170
references.citation: Nat Med. 2007 Jul;13(7):857-61
references.pmid: 17603495
references.citation: J Infect Dis. 2009 Apr 1;199(7):926-35
references.pmid: 19236279
references.citation: J Virol. 1999 Jul;73(7):6188-90
references.pmid: 10364381
references.citation: Vaccine. 1999 Jan;17(1):40-9
references.pmid: 10078606
references.citation: Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5850-5
references.pmid: 18413606
references.citation: Virology. 2005 Jul 5;337(2):365-72
references.pmid: 15885736
references.citation: JAMA. 2007 Aug 15;298(7):743-53
references.pmid: 17699008
references.citation: Virology. 2011 Jan 20;409(2):348-59
references.pmid: 21074234
references.citation: Virology. 1995 Aug 1;211(1):204-8
references.pmid: 7544045
references.citation: Methods Mol Med. 2005;119:445-62
references.pmid: 16350417
references.citation: Genes Dev. 2009 Jan 15;23(2):181-94
references.pmid: 19131434
references.citation: J Virol. 1995 Jun;69(6):3959-63
references.pmid: 7745754